Leslie Tari is CHIEF SCIENTIFIC OFFICER at Cidara Therapeutics, Inc. (CDTX). They have made 9 open-market trades across 1 company since 2022, most recently 2025-03-11.
CIK 0001870270
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2023, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CDTX | 16,215 | $3.6M |
Shares reported on the most recent Form 4, priced at the 2025-03-13 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CDTX | SELL | 2025-03-11 | 2025-03-13 | $21.96 | $39K | -1.3% | -16.0% | +16.2% |
| CDTX | SELL | 2024-09-11 | 2024-09-13 | $11.64 | $11K | -9.9% | -14.2% | +80.2% |
| CDTX | SELL | 2024-03-11 | 2024-03-12 | $0.67 | $14K | +15.9% | +28.8% | +0.1% |
| CDTX | SELL | 2023-09-11 | 2023-09-13 | $0.95 | $18K | -12.6% | -17.1% | -35.6% |
| CDTX | BUY | 2023-08-14 | 2023-08-14 | $0.97 | $10K | -18.0% | +19.2% | -17.0% |
| CDTX | SELL | 2023-03-13 | 2023-03-13 | $1.53 | $12K | -17.3% | -37.0% | -28.9% |
| CDTX | SELL | 2023-01-12 | 2023-01-27 | $1.20 | $14K | +41.3% | +20.7% | -14.0% |
| CDTX | SELL | 2022-09-12 | 2022-09-13 | $0.68 | $12K | -5.4% | -16.5% | -25.6% |
| CDTX | SELL | 2022-01-05 | 2022-01-07 | $1.25 | $2K | -18.0% | -20.2% | -20.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.